detoxified shigella flexneri 2a artificial invasin complex

Vaccineexperimental

Clinical trial activity

2 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Apr 23, 2019 (NCT03869333)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05961059Phase 1Nov 30, 2023Centre for Infectious Disease Research in Zambia (CIDRZ), European and Developing Countries Clinical Trials Partnership (EDCTP), European Vaccine Initiative (EVI), Heidelberg, Germany, Leiden University, PATH, United States Army, University of Gothenburg
NCT03869333Phase 1Apr 23, 2019PATH, United States Navy
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PATHAcademic/Hospital2112019
Centre for Infectious Disease Research in Zambia (CIDRZ)Academic/Hospital1012023
European and Developing Countries Clinical Trials Partnership (EDCTP)Academic/Hospital1012023
European Vaccine Initiative (EVI), Heidelberg, GermanyGovernment1012023
Leiden UniversityAcademic/Hospital1112023
United States ArmyGovernment1012023
United States NavyGovernment1012019
University of GothenburgAcademic/Hospital1012023
8 organizations
Page 1 / 1